| Literature DB >> 34641920 |
Hassan Maleki1,2, Kamyar Khoshnevisan3,4,5, Sayed Mahmoud Sajjadi-Jazi6,7,8, Hadi Baharifar9,7, Maryam Doostan10, Nazanin Khoshnevisan7, Farshad Sharifi7,11,8.
Abstract
Diabetic mellitus (DM) is the most communal metabolic disease resulting from a defect in insulin secretion, causing hyperglycemia by promoting the progressive destruction of pancreatic β cells. This autoimmune disease causes many severe disorders leading to organ failure, lower extremity amputations, and ultimately death. Modern delivery systems e.g., nanofiber (NF)-based systems fabricated by natural and synthetic or both materials to deliver therapeutics agents and cells, could be the harbinger of a new era to obviate DM complications. Such delivery systems can effectively deliver macromolecules (insulin) and small molecules. Besides, NF scaffolds can provide an ideal microenvironment to cell therapy for pancreatic β cell transplantation and pancreatic tissue engineering. Numerous studies indicated the potential usage of therapeutics/cells-incorporated NF mats to proliferate/regenerate/remodeling the structural and functional properties of diabetic skin ulcers. Thus, we intended to discuss the aforementioned features of the NF system for DM complications in detail.Entities:
Keywords: Cell transplantation; Delivery systems; Diabetic wound; Electrospinning; Nanofiber; Scaffold; Wound dressing
Mesh:
Year: 2021 PMID: 34641920 PMCID: PMC8513238 DOI: 10.1186/s12951-021-01065-2
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Utilization of nanofiber-based systems for treatment of DM through several approaches
Fig. 2Fibers with multifarious morphologies prepared by electrospinning. a–d Different NF assembly morphologies: a random oriented, b aligned as well as (c) patterned and (d) spider-web-like nano-fiber/net structures. e–q Various single NFs with (e) bead-on-string, (f) ribbon-like, (g) helical, (h) porous [30], (i) necklace-like, (j) firecracker-shaped, (k) rice grain-shaped, (l) core—shell, (m) multichannel tubular, (n) multi-core cable-like, (o) tube-in-tube, (p) nanowire-in-microtube and (q) hollow structures.
Reproduced with permission from Ref. [21]
Fig. 3Functionally active insulin released from insulin-loaded nanofibrous scaffolds to accelerate the healing wound
Reproduced with permission from Ref. [87]
Various characteristics of nanofibrous delivery systems incorporated with insulin
| Type of polymer/material | Diameter of nanofiber (nm) | Applied cell type/animal | Main finding | Refs. |
|---|---|---|---|---|
| PuraMatrix™ | –a | Male Wistar rats | PGLmarkedly decreased and maintained up to 24 h via subcutaneous route | [ |
| PVA- | 100–600 | – | Nanofibers with the electrochemically controlled release system | [ |
| PLGA/nHA-I | 520 | Osteoblastic cells (MC3T3-E1) | Accelerate the cell adhesion, proliferation, and differentiation of the osteoblastic cells | [ |
| PLGA | 432 ± 106 | Atrial fibroblasts/prague–Dawley rats | Supported accelerated wound healing and favored epithelial cell proliferation | [ |
| FSP | 360 ± 37 | Caco-2 cells | Physically protect the degradation of insulin and increased transport crossing the cell monolayer | [ |
| PVA/NaAlg | 300–400 | Induced diabetes Wistar rats | The composite nanofibers serve as an ideal carrier for the delivery of insulin via the sublingual route | [ |
| CS/PEO | 200–2000 | 3T3-L1 preadipocyte cells/ex-vivo porcine buccal mucosa | Nanofiber mats capable of delivering insulin via the buccal mucosa | [ |
aNot available data in the article
PuraMatrix™ acetyl-(Arg-Ala-Asp-Ala)4-CONH2, PGL plasma glucose level, PVA poly (vinyl alcohol), PE poly(ethylene), CS Chitosan, PLGA/nHA-I poly(lactide-co-glycolide)/insulin-grafted hydroxyapatite nanorods, FSP fish sarcoplasmic protein, NaAlg sodium alginate, PEO poly(ethylene oxide)
NFs mediated GFs and genes delivery systems intended for diabetic complications
| Type of polymer/material | Incorporated/modified agents | Diameter of nanofiber (nm) | Applied cell type/animal | Main finding | Refs. |
|---|---|---|---|---|---|
| HMPA | –a | 10−20 | Male Sprague−Dawley rats | Increase wound recovery, formation, and blood vessel density | [ |
| HBPA | VEGF and FGF-2 | – | – | Transplant recipients achieved normoglycemia at a higher rate (78%) than control animals | [ |
| Peptide/heparin hybrid | HGF | – | Rat insulinoma β-cell line INS-1/adult male rats | HGF-loaded KLD2R/Hep gel improve β-cell survival and insulin secretion | [ |
| PCL | GO and VEGF | 10,000 | HUVECs | Increase expression of the eNOS gene in the VEGF signaling pathway | [ |
| PCL-PEG block copolymers | DNA | – | NIH3T3 cells/mice | More effective than naked DNA in terms of in vivo transfection | [ |
| PCL–PEG block copolymer | Small interfering RNA | – | Dermal fibroblasts/female C57BL/6 mice | The delivery system increased the MMP-2 gene-silencing and neo-collagen accumulation at the wound sites | [ |
| PCL–PEG diblock copolymer | hEGF | – | HDFs/female C57BL/6 mice | High hEGF expression level, significantly accelerated wound recovery rates at diabetic ulcer site | [ |
| PCL and PEG | bFGF and EGF | – | HDF cells/female C57BL/7 mice | Release system increases tissue recovery | [ |
| PCL/PEG/PCL triblock copolymer | hEGF | – | Human primary keratinocytes/female C57BL/6 mice | The NFs improved in vivo wound healing | [ |
| PLGA | Vancomycin, gentamicin, and PDGF | 371 ± 162 to 655 ± 206 | Human fibroblasts/Sprague–Dawley rats | The NFs increased amount of angiogenesis marker (CD31) and accelerated healing in the early stage | [ |
| PLAGA | FTY720 | – | C57b16/j male mice | The significantly increased the length density of vessels in the moderately diabetic mice | [ |
| PLA-PVA | CTGF | 2600 ± 1400 | 3T3 fibroblasts, HaCat keratinocytes, and EA.hy926 endothelial cells | CTGF loaded core–shell NFs improved cell viability, cell proliferation, and cell migration at ulcer site | [ |
| PELA | bFGF | 783 ± 129 | MEF/skin regeneration for diabetic rats with dorsal wounds | The release system improved collagen deposition and ECM remodeling at diabetic ulcer site | [ |
| PLGA/CNC composite | Neurotensin | 380 ± 28 | Round 0.6-cm-diameter full-thickness dermal wounds in mice | The composite NFs promote rapid healing than control groups during 2 week | [ |
| Col/HA | VEGF, PDGF, bFGF and EGF | HA: 486 + 151 Col: 534 ± 128 | HUVECs/induced diabetic rats | The delivery system accelerated wound closure rate, with elevated collagen deposition and enhanced maturation of vessels | [ |
| Eudragit RL/RS 100 | Gentamicin and rhEGF | – | Female C57BL/6 mice | The NFs mesh showed acceptable antibacterial activity and In vivo work induced faster wound healing in dorsal wounds | [ |
| PHBV/gelatin methacryloyl | EGF | 900 ± 600 to 3500 ± 1800 | 3T3 fibroblasts, HaCat keratinocytes and EA.hy926 endothelial cells | Promoting keratinocytes, fibroblasts and endothelial cells migration and proliferation and enhanced angiogenesis and in vivo wound healing | [ |
aNot available data in the article
HMPA Heparin mimetic peptide amphiphile, HGF hepatocyte growth factor, PCL polycaprolactone, GO graphene oxide, VEGF vascular endothelial growth factor, HUVEC human umbilical vein endothelial cell, PEG polyethylene glycol, hEGF human epidermal growth factor, HDF human dermal fibroblasts, bFGF basic fibroblast growth factor, PLGA poly lactic-co-glycolide, PDGF platelet-derived growth factor, PLA polylactic acid, PVA poly vinyl alcohol, CTGF connective tissue growth factor, NF nanofiber, PELA poly(ethylene glycol)-poly(dl-lactide), CNC cellulose nanocrystal, MEF mouse embryo fibroblasts, HA hyaluronic acid, Col collagen, PHBV poly 3-hydroxybutyrate-co-3-hydroxyvalerate
Fig. 4NFs preparation process for immobilization of four different GF using gelation NPs and dual
source dual power ES. Reproduced with the permission from reference [101]
Fig. 5Schematic illustrating the device-less (DL) procedure and DL in the combination of SiO2-VEGF scaffolds for IT at subcutaneous. It comprised of 3 steps including: A A silicone/nylon catheter was pre-implanted subcutaneously (A1) (red arrow) to prevascularization and removed after 14 days; B islet isolation and SiO2-VEGF NFs wrapping (Blue mats = NFs, yellow dots = VEGF). (B1: wrapped islets; B2: expanded mouse islet for isolation; B3: syngeneic islets are isolated and collected (bar = 100 µm); B4. islet viability is detected by live/dead assay (bar = 100 µm)); C islet or wrapped islet (C1) transplantation in the prevascularized percutaneous cavity in diabetic mice. Reproduced with the permission from reference [113]
Fig. 6Schematic diagram describing the use of 3D scaffolds comprised of radially or vertically aligned NFs together with BMSCs for the treatment of DWs along with their potential mechanisms. A Illustration of radially aligned NFs applied for healing stage 0 and stage 1 DFU, with the potential mechanisms comprising improving angiogenesis, granulation tissue formation, ECM deposition, and re-epithelialization (C). B Illustration of vertically aligned NFs applied for healing stage 3 and stage 4 DFU, with the potential mechanisms comprising improving promoting granulation tissue formation, angiogenesis, and ECM deposition (D). Reproduced with the permission from Ref. [129]
The characteristics of fibrous scaffolds applied in cell delivery and TE intended for treating DM
| Type of polymer/material | Incorporated/modified agents | Diameter of fibers (nm) | Applied cell type to differentiation | Main achievement/application | Refs. |
|---|---|---|---|---|---|
| Glucagon-like peptide 1 | –a | 10 | Rat insulinoma cells | A proper cell-encapsulating network for enhanced activity and proliferation of IPCs | [ |
| Heparin mimetic peptide amphiphilic | VEGF and FGF2 | 20–30 | Pancreatic islet | Nanofiber gel platform for islet culture and transplantation | [ |
| PCL | – | 200 | hiPSCs | An ideal scaffold for differentiation of hiPSCs in 3D culture | [ |
| SF and pig pancreatic decellularized ECM | – | 97–707 | Mouse islet | A promising candidate for pancreatic TE | [ |
| CA, PES, and PTFE | – | 365 ± 136 (CA), 224 ± 140 (PES), 261 ± 140 (PTFE) | – | Potential for islet cell encapsulation application | [ |
| PVA /Silicone | VEGF | 4–10 | Mouse islet | The ECM to improve the vitality of subcutaneous islet transplantation | [ |
| SF/PLA | – | – | Conjunctiva MSCs | A potential supportive matrix for islet TE | [ |
| Polyamide | Laminin | – | Pancreatic β cell | Providing an ECM-like system for islet culture | [ |
| PCL/poly-D-lysine | MIN6 cell membrane | 50–280 | Pancreatic β cell | As scaffolds to culture beta cells | [ |
| PES | – | – | hiPSCs | A 3D matrix to enhance pancreatic differentiation of hiPSCs | [ |
| PES | Collagen coating | – | hiPSCs | As a potential scaffold for pancreatic TE and regenerative medicine applications | [ |
| PLLA/PVA | Oxygen modification | – | hiPSCs | As an ideal scaffold to provide a microenvironment for pancreatic differentiation | [ |
| PLLA/PVA | – | – | hADSCs | A suitable option in pancreatic TE | [ |
| PLA/CS | – | 70,000 | Human Wharton’s jelly MSCs | A precursor for cell transplantation for diabetes treatment | [ |
| PLA/CS | – | 70–100 | EnCSs | An ideal scaffold for IPCs development for diabetes mellitus cell therapy | [ |
| Silk | – | – | hiPSCs | A great potential to use in clinical pancreatic TE application | [ |
| Silk/PES | – | – | hADSCs | As a supportive matrix to mimic 3D in vivo microenvironment | [ |
| PHBV | – | 900 ± 600 | hiPSCs | As a promising cell-copolymer construct for pancreatic TE | [ |
| PVA | Oxygen plasma | – | hADSCs | A new approach for pancreatic TE and β cell replacement therapies | [ |
| PCL/PVA | – | – | hiPSCs | A new approach to beta-like cells replacement therapies and pancreatic TE | [ |
| Polyacrylonitrile | – | 250 | Human endometrial cells | Transplantation of pancreatic precursor from endometrium for the treatment of diabetes | [ |
| PCL/gelatin | – | – | Rat CD93+ hematopoietic stem cells | As a more appropriate tissue‐engineered construct in DW repair | [ |
| PCL/pluronic-F-127 | – | – | Bone marrow MSCs | Personalized 3D scaffolds with controlled structure for DW healing | [ |
| Natural and artificial acellular dermal matrix | Graphene oxide- PEG-mediated quercetin | – | MSCs | A suitable architecture and environment for cell attachment and proliferation | [ |
aNot available data in the article
PCL polycaprolactone, hiPSCs human-induced pluripotent stem cells, CS Chitosan, SF silk fibroin, VEGF vascular endothelial growth factor, FGF2 fibroblast growth factor 2, TE tissue engineering, ECM extracellular matrix, CA cellulose acetate, PES polyethersulfone, PTFE polytetrafluoroethylene, PVA polyvinyl alcohol, PLA polylactic acid, PLLA poly (l-lactic acid), MSC mesenchymal stem cell, hADSC human adipose-derived stem cells, hESCs human embryonic stem cells, EnSCs endometrial stem cells, IPCs insulin-producing cells, PHBV poly(3-hydroxybutyrate-co-3-hydroxyvalerate), PEG polyethylene glycol
Fig. 7Conceptual design of an asymmetric wettable composite mat consisting PCL-Gel-Pio for DW healing.
Reproduced with permission from Ref. [148]
Fig. 8Conceptual design of Ca7P2Si2O16-loaded conducive PCL/Gel for wound healing process in diabetic mice.
Reproduced with permission from Ref. [150]
Fig. 9Schematic illustration of the absorbable thioether grafted hyaluronic acid nanofibrous hydrogel for synergistic modulation of the inflammation microenvironment to accelerate chronic DW healing. Illustration of the preparation procedure of FHHA-S/Fe, dressing of FHHA-S/Fe on full-thickness wound model in diabetic C57BL/6 mouse, and the mechanism of FHHA-S/Fe for enhanced chronic wound healing effect.
Reproduced with permission from Ref. [133]
Fig. 10Schematic illustration of CS-PVA- electrospun NFs intended for chronic and acute wounds.
Reproduced with permission from Ref. [162]
Fig. 11Schematic illustration of BC/Gel mats loaded with Gb and Met.
Reproduced with permission from Ref. [163]
Fig. 12Schematic illustration of an electrospun copper-based MOF (HKUST-1) applied for the acceleration of DW healing process.
Reproduced with permission from Ref. [168]
Fig. 13Conceptual design of heparin implanted Cur embedded aligned mats.
Reproduced with permission from Ref. [172]
Fig. 14Schematic representation of the experimental design describing (a) methodology to prepare bioactive silk dressings by modifying spider SF proteins on top of SF nanofibrous mats and (b) approach of acting cutaneous wounds in a diabetic rabbit model by silk mats; DM condition was found for 28 days before wounding, mats were replaced after 3 days for 12 days, and groups were accomplished on day 7, 14, and 21 as indicated by (T) in the sketch.
Reproduced with permission from Ref. [177]
Findings of electrospun NF mats loaded with or without therapeutic agents for wound healing applications
| Type of polymer/material | Incorporated/modified agents | Diameter of nanofiber (nm) | Applied cell type/animal | Main finding | Refs. |
|---|---|---|---|---|---|
| PVA/PLA | Met and FSP | 621–681 | HaCaT cell lines | Suitable properties for proliferation, and attachment of cells | [ |
| Curdlan/PVA | 1% AgNO3 | 92 ± 33 | RAW 264.7 macrophage Cells/wister rats | Better cell viability, proliferation, and wound healing ability | [ |
| SF/PVA | Non-mulberry SF, mulberry Bombyx mori SF | 100–300 | Endothelial cells/Alloxan induced diabetic rabbit | The functional benefit of regulating ECM secretion from fibroblast | [ |
| PCL | Cur | 200–1000 | Epidermis-diabetic mice | Reducing inflammatory induction, as evidenced by low levels of interleukin‐6 release from mouse monocyte–macrophages seeded | [ |
| PCL/GT | Cur | –a | Fibroblast, and epidermal cell/diabetic rats | Lessening blood glucose level | [ |
| PCL/Gel | AV and HPO | – | TNF-α in serum samples/Wistar Albino male rats | Reducing oxidative stress index | [ |
| PCL-based | Sodium percarbonate | 473 ± 90 | Thick epithelium-rats | Generation of chemical-based oxygen exposed angiogenesis stimulation | [ |
| PCL/CS/Gel and PCL/PVP | Met and Pio | 138.0 ± 42.5 | Complete epidermis and dermis/type-1 diabetic rats | better regeneration and lower TNF-α and NF-κB levels than single drug therapies, good cytocompatibility with L929 cells, and an ideal area for the proliferation | [ |
| PCL-based | Gel-Pio | 144.9 ± 56.92 | Epidermal cell-Type 1, and 2 diabetic mice | Promoting angiogenesis and cell proliferation and regulating the expression of MIP-2, VEGF, TNF-α, IL-1β, IL-6, MMP-9, and TGF-β | [ |
| PLCL | ZnO NPs, and oregano essential oil | 1040 ± 220 | Epidermis, thick VEGF/stained tissue-rats | anti-inflammatory effect by down-regulating inflammatory-related gene expression | [ |
| PCL/Gel | Nagelschmidtite (Ca7P2Si2O16) particles | 800–2000 | Epidermal cells-diabetic mice | Improving epidermal regeneration, angiogenesis, collagen deposition, and lessening inflammatory response | [ |
| co-axial PCL /collagen | DMOG | 391.42 ± 31.27 | Epidermal and epidermis-T1DM rats | Enhancing the re-epithelialization, angiogenesis, and wound closure | [ |
| PCL/GT/PVA | MSCs | 130 ± 19 | Epidermis/rats | Repair and regeneration including re-epithelization and collagen formation | [ |
| PCL/PVA/CS | – | 125 ± 12 | Epidermis and dermis-rats | Higher rate of healing process | [ |
| Absorbable nanofibrous hydrogel | FHHA‐S/Fe | 60 ± 11 | Epidermis/mice | Antioxidant properties and the capability of transforming the macrophage phenotype | [ |
| Hydrogel-based | Gel encapsulated-polydeoxyribonucleotide | – | Human embryonic fibroblast cells, vascular endothelial cells/diabetic skin ulcer mouse model | levels of cytokines and angiogenic factors increased in the treatment groups | [ |
| Hydrogel formulation | 5% Turmeric, 1% Oregano, and 1% CS | 211 | Epidermis-rats | High anti-inflammatory, and antioxidants activities, as well as accelerated the healing process in pressure ulcers | [ |
| TEMPO-oxidized SCNF and microfludized SCNF | Hydrogel-based mats including SCN5, T033SC, and T050SC | 753.36 ± 103, 825.54 ± 109, and 496.54 ± 39 | Endothelial cell marker, cluster of differentiation 31 (CD31) | Acceleration of the wound healing with forming nearly the same as normal tissue and providing the healed wound with a functional tissue | [ |
| HPMC and PEO | βG | 81 ± 39 | db/db mice | βG-nanofiber significantly improved the healing as compared to the non βG-nanofibers | [ |
| CS/PCL/PVA | MSc + Met | 113 ± 43 | Epidermis and dermis, and fibroblasts differentiate into myofibroblasts | Unique physico-chemical and biological properties of mats, introducing a slow-releasing and dual-functioning scaffold which reduces scar formation and accelerates the wound healing | [ |
| CS/PVA | – | 280 | Epidermis and dermis-rats | Acceleration in diabetes wound healing | [ |
| CS/PVA | ZnO | 279.34 ± 7.23 | Epidermis and scar tissue-rabbits | Useful dressing materials for DWs | [ |
| Gel-based | Cur and Lithospermi radix extract | ~ 100 | STZ-induced diabetic rat mode | Enhancing collagen synthesis, TGF-β production, anti-inflammatory effect, and promoted the wound healing process | [ |
| CS-PVA | Nano-bioglass | 800 ± 400 | Epidermis-rats | Upregulating growth factors of VEGF, TGF-β and downregulating inflammatory cytokines of TNF-α, IL-1β | [ |
| Cellulose/Gel | Met and glybenclamide | 220 ± 90, and 390 ± 10 | Proliferation of L929 (mouse fibroblast) cells/T1DM rats | Observing the highest decrease of TNFα level | [ |
| CA/zein | Sesamol | 150–250 | Diabetic mice | Reducing the expressions of inflammatory factors and IL-10, and sesamol, which can up-regulate IL-6 expression, promoting the growth and proliferation of keratinocytes | [ |
| PU/CMC) | 277 ± 20 | Epithelium/male Wister rats | Increasing macrophage infiltration, neovascularization activity, fibroblastic proliferation, and regeneration of collagenization and epithelium | [ | |
Cobalt-based MOF ZIF-67-PLA/Gel | Dimethyloxalylglycine, DMOG | 300–500 | Epidermal cells and the complete epithelium-/STZ-induced diabetic mice | Enhancing angiogenesis, collagen deposition, elimination of inflammation in the DW, and promoting DW healing | [ |
| Cu-GO | Zein | 152.9 ± 14 | Epidermal/diabetic rats | The highest transformation of granulation tissue, Epidermal reepithelialization | [ |
| copper-based MOF, namely, HKUST-1 | Nitric oxide as a gas medicine | ~ 500 | Complete epithelium/mice | Synergistically stimulate angiogenesis, promote collagen deposition, and inhibit inflammation | [ |
| Si-ACP/PM | - | 40 | Human umbilical vein endothelial cells in vitro and epidermis and dermis-mice | Improved angiogenesis, reepithelialization, and collagen deposition in the wound site, which ultimately accelerates the progress of the DW healing | [ |
| PLGA/collagen | Glucophage | 203 ± 41 | Epidermis-diabetic rats | Increasing collagen content and can act as an effective tissue-engineering scaffold for regenerating skin | [ |
| PLGA | Met | 443 ± 121 | Epidermis-T1DM rats | Providing faster wound healing and better re-epithelialization | [ |
| PLGA-based | Cur, and heparin | 220 ± 16 | Epithelium-rats | Acceleration of re-epithelization, higher angiogenesis, and collagen deposition | [ |
| PLGA/SF | – | 167 ± 50 | Fibroblasts (L929) -rats | Decreasing the wound area in excision wound model in diabetic rats | [ |
| PLGA/Gel | Lira | 636 ± 198 | Diabetic dermal wounds- rats | Promoting angiogenesis, AKT/GSK-3β/β-catenin pathways | [ |
| pGlcNAc fiber mats | – | – | db/db mouse | Hemostatic and wound healing effects | [ |
| Aminated PES | Human umbilical cord blood-derived CD34+ cells | – | Dermal and myofibroblasts-mice | Resolving inflammation, augmentation of angiogenesis, improving epithelialization and granulation tissue formation | [ |
| Porous PLA | Asiatic acid | – | Diabetic mice | Accelerating re-epithelization, angiogenesis and ECM formation | [ |
| GO-PEG | Quercetin as mediator and artificial acellular dermal matrix | 402.71 ± 123.87 | MSC/rats | Promotion of collagen deposition Enhancement of angiogenesis for DW healing at an early stage | [ |
| Various recombinant spider silk fusion proteins | – | Complete epidermal-rabbits | Acceleration of the wound healing rate, improvement of angiogenesis, early re-epithelialization, and collagen synthesis | [ | |
| Bioactive glass nanofibres | – | 500–900 nm | oral mucosal wound-T1DM-rabbits | Epithelial cell migration at a short time, providing a sterile wound bed and increasing VEGF precursor | [ |
| PLA | DCH | 424 ± 62 | Epidermal and dermal layers-diabetic rats | enhancing the chronic wound healing, and have great superiority over topical coating of DCH solution | [ |
aNot available data in the article
T1DM type 1 diabetes, PVA poly vinyl alcohol, PLA polylactic acid, Met metformin, FSP fish sarcoplasmic protein, SF silk fibroin, ECM natural extracellular matrix, PCL polycaprolactone, Cur curcumin, GT gum tragacanth, Gel gelatin, AV Aloe Vera, HPO hypericum perforatum oil, TNF-α tumor necrosis factor alpha, NF-κB nuclear factor kappa B, CS chitosan, PVP polyvinylpyrrolidone, Pio pioglitazone, PLCL poly (l-lactide-co-caprolactone), DMOG dimethyloxalylglycine, ZnO NPs zinc oxide nanoparticles, VEGF vascular endothelial growth factor, GT gum tragacanth, MSC mesenchymal stem cells, FHHA‐S/Fe thioether grafted hyaluronic acid nanofibers, TEMPO 2,2,6,6-tetramethylpiperidinyloxy, SCNF sacchachitin nanofibers, βG beta-glucan, HPMC hydroxypropyl methylcellulose, PEO polyethylene oxide, STZ streptozotocin, TNF-β tumor necrosis factor-beta, IL Interleukin, CA cellulose acetate, ECM extracellular matrix, PU polyurethane, CMC carboxymethyl cellulose, MOF metal–organic framework, DW diabetic wound, GO graphene oxide, Si-ACP/PM silicon-doped amorphous calcium phosphate nanocoating on the surface, PLGA poly lactic-co-glycolide, Lira liraglutide, pGlcNAc poly-N-acetyl glucosamine, PES polyethersulfone, PEG polyethylene glycol, DCH doxycycline
Fig. 15The global advanced wound care market size from 2019 to 2026. BN billion, CAGR compound around growth rate